Deal Terms and Structure
Tempus AI (NASDAQ: TEM) has agreed to acquire the remaining shares of Personalis (NASDAQ: PSNL) it does not already own, at $16.25 per common share. The total enterprise value is $1.5 billion, net of Tempus’ existing stake. The offer represents a 6% premium to Friday’s close and a 28% premium to the unaffected 30-day VWAP.
Consideration is structured as 100% stock, with Tempus retaining the option to substitute cash for up to 50% of total payment. Personalis shareholders will receive a floating exchange ratio of Tempus common stock, capped at a maximum of 0.3356 shares of TEM per PSNL share, to be finalized near closing. Any cash portion will be funded from existing cash and credit facility borrowings. Closing is targeted for late 2026 or early 2027, pending shareholder approval and regulatory clearance.
Strategic Rationale: MRD Market Expansion
The acquisition extends Tempus’ footprint in minimal residual disease testing, a segment central to post-treatment cancer monitoring. Personalis’ NeXT Personal platform is positioned on sensitivity: detecting circulating tumor DNA at levels below what most competing assays can resolve, which supports earlier recurrence detection and more granular treatment-response tracking. Medicare coverage already extends to three indications, with additional coverage decisions pending.
This is a deepening rather than a new relationship. Tempus took an equity stake in Personalis in November 2023 and has commercialized NeXT Personal since. The acquisition converts that commercial partnership into full integration of Personalis’ assay technology with Tempus’ multimodal data and AI infrastructure, aimed at biomarker discovery and longitudinal monitoring at scale.
Market Sizing
Roughly 2.1 million new cancer diagnoses are projected in the US this year, against a backdrop of improving survival rates that extend the monitoring window per patient. MRD testing sits at the intersection of both trends: more patients entering surveillance, and each surveillance period lasting longer. Tempus is framing the deal as a bet on adoption and reimbursement momentum building faster than the market currently prices in.
Personalis Q2 Preliminary Numbers
Personalis reported preliminary Q2 revenue of $22.4 million on 10,384 clinical tests, a 33% sequential increase in test volume. Volume growth of that magnitude, arriving alongside the acquisition announcement, reads as validation of the commercial trajectory Tempus is underwriting rather than a standalone catalyst — the deal price was negotiated ahead of this print becoming public.
What It Means for Investors
For Personalis holders, the transaction converts an illiquid, single-product diagnostics name into TEM exposure at a fixed (capped) exchange ratio, with an embedded cash option at Tempus’ discretion. The premium is modest against unaffected price (6%) but substantial against the 30-day VWAP (28%), suggesting the deal was priced against a stock that had already begun re-rating on speculation, not a flat baseline.
For Tempus, the acquisition is a vertical integration play: owning the assay technology outright removes a partner-margin layer on a product line it already commercializes, and consolidates control over the diagnostic asset most levered to the MRD growth thesis. The stock-heavy structure also means TEM is using its own equity as acquisition currency — a signal of confidence in valuation, but one that dilutes existing holders proportionally to deal size and final exchange ratio.